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ABSTRACT
Background. The severe inflammatory state secondary to Covid-19 leads to a severe 
derangement of hemostasis that has been recently described as a state of disseminated 
intravascular coagulation (DIC) and consumption coagulopathy, defined as decreased 
platelet count, increased fibrin(ogen) degradation products such as D-dimer as well as 
low fibrinogen.
Aims. Whole blood from 24 patients admitted at the intensive care unit because of Covid-
19 was collected and evaluated with thromboelastography by the TEG point-of-care 
device on a single occasion and six underwent repeated measurements on two 
consecutive days for a total of 30 observations. Plasma was evaluated for the other 
parameters of hemostasis. 
Results. TEG parameters are consistent with a state of hypercoagulability as shown by 
decreased R and K values, and increased values of K angle and MA. Platelet count was 
normal or increased, prothrombin time and activated partial thromboplastin time were 
near(normal). Fibrinogen was increased and D-dimer was dramatically increased. C-
reactive protein was increased. Factor VIII and von Willebrand factor (n=11) were 
increased. Antithrombin (n=11) was marginally decreased and protein C (n=11) was 
increased. 
Conclusion. The results of this cohort of patients with Covid-19 are not consistent with 
acute DIC, rather they support hypercoagulability together with a severe inflammatory 
state. These findings may explain the events of venous thromboembolism observed in 
some of these patients and support antithrombotic prophylaxis/treatment. Clinical trials 
are urgently needed to establish the type of drug, dosage and optimal duration of 
prophylaxis.
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Essentials
 Covid-19 is associated with a considerable derangement of hemostasis, described 
as DIC
 Covid-19 is associated with hypercoagulability as shown by whole blood 
thromboelastography
 Covid-19 patients are candidate to antithrombotic prophylaxis/treatment
 Clinical trials are urgently needed to establish appropriate antithrombotic regime 
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INTRODUCTION
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for 
the pandemic outbreak across the Word [1, 2]. The clinical condition that is associated 
with the infection has been named Covid-19. The major clinical challenge associated with 
Covid-19 is severe, often fatal, interstitial pneumonia [3]. The severe inflammatory state 
secondary to the infection leads to a severe derangement of hemostasis typically 
observed in patients with sepsis and has been described as a state of acute 
disseminated intravascular coagulation (DIC), based on decreased platelet count, 
prolonged prothrombin and activated partial thromboplastin time (PT/APTT), increased 
fibrin(ogen) degradation products such as D dimer as well as low fibrinogen [4]. Clinical 
observations made on a series of patients admitted to the intensive care unit (ICU) of our 
hospital, showed however that a certain number of patients with Covid-19 developed 
clinical signs of pulmonary embolism and/or deep vein thrombosis of the lower limbs 
(unpublished observations). The diagnosis of pulmonary embolism in these patients has 
not been confirmed with imaging or autopsy in all patients, as in most cases the former 
was not promptly available and the latter is currently not allowed in all hospitals by health 
authorities. However, pulmonary embolism diagnoses are supported by the fact that most 
(up to 1/3) Covid-19 patients had deep vein thromboses of the lower limbs as shown by 
compression ultrasonography. Since a thromboelastography point of care device was 
available in the ICU, we decided to collect viscoelastic observations in some of the Covid-
19 patients.
PATIENTS AND METHODS
Patients
We evaluated on a single occasion 24 intubated Covid-19 patients, randomly selected 
from those admitted to the ICU because of acute respiratory syndromes. Six of these 
patients underwent repeated measurements on two consecutive days thereafter, thus 
totaling 30 observations. Blood was collected from an arterial line. One mL of native 
whole blood was used to perform thromboelastography and 3.5 mL were collected into A
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vacuum tubes (Becton and Dickinson, Plymouth, UK) containing 1/10 volume of 0.109 M 
trisodium citrate and  centrifuged for 15 minutes (controlled room temperature) at 2,500g. 
The supernatant plasma was used to perform tests of hemostasis. 
Methods
Thromboelastography. Tests were carried out by TEG (Haemonetics TEG 5000, 
Braintree, MA), an vitro point of care device, able of assessing the viscoelastic properties 
of clotting native whole blood upon activation of hemostasis by exogenously added 
triggers (kaolin). The assay system mimics to some extent what occurs in vivo with the 
contribution of blood cells, platelets and plasma. TEG evaluation was performed in the 
presence of heparinase, meant to quench heparin as most of the patients were on 
prophylaxis with low molecular weight (LMWH) or unfractionated heparin. We recorded 
the following parameters. R (minutes), which is a measure of the clotting time from the 
point of coagulation ignition to the appearance of the clot; K (minutes) and K angle, which 
define the velocity of  clot formation; MA (mm), which defines the maximal amplitude of 
the clot; Lys-30, which defines the percentage decrease of clot amplitude at 30 minutes 
post-MA. Accordingly, short R, K or Lys-30 as well as high K angle or MA denote 
hypercoagulability. 
Other tests of coagulation. PT and APTT were measured by means of commercial 
reagents, Recombiplastin 2G, or Synthasil APTT, respectively (Werfen, Orangeburg, 
NY). D dimer and fibrinogen were measured by means of an immunoturbidimetric latex-
particle assay or the functional clotting assay according to Clauss, respectively (Werfen). 
Antithrombin and protein C activities were measured by commercial kits (Werfen). Protein 
S was measured as the free antigen and factor VIII was measured by the one-stage 
clotting assay based on APTT and factor VIII-deficient plasma (Werfen). von Willebrand 
factor antigen and ristocetin cofactor activity were measured by means of commercial kits 
(Werfen). All tests were performed on the automated coagulometer ACLTop (Werfen, 
Bedford, MA). PT and APTT results were expressed as ratio of patient clotting time to the 
clotting time of a pooled normal plasma prepared and routinely used in our laboratory. 
Results of the other parameters were expressed as activities relative to the pooled A
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normal plasma to which an arbitrary potency of 100 U/dL was assigned or as 
concentrations. 
RESULTS AND DISCUSSION
Thromboelastography. Twenty-four patients were evaluated by the TEG on a single 
occasion and six underwent repeated measurements on two consecutive days thereafter 
for a total of 30 observations. Table 1 shows the viscoelastic as well as hemostasis and 
other biochemical results. Their values have been compared with the mean of the 
respective reference range, previously established in our laboratory using 40 heathy adult 
subjects. R and K values were shorter than the mean value of the reference population in 
50% and 83% of the Covid19 population, respectively. K angle and MA values were 
higher than the mean value of the reference population in 72% and 83% of the Covid-19 
population, respectively. Lys-30 was lower than the mean of the reference population in 
100% of the Covid-19 population. Fig 1 shows that the distribution of the results for the 
maximal clot amplitude (i.e., MA) in the patient population was skewed towards higher 
than normal levels. Fig 2 shows typical TEG tracings for a patient with Covid-19 and a 
healthy control. Collectively, the thromboelastographic results in patients with Covid-19 
denote a state of hypercoagulability. 
Other parameters of hemostasis. The other tests of hemostasis are shown in Table 1. 
PT and APTT were normal or slightly prolonged; mean ratio values and range (min–max) 
were 1.16 (0.99-1.50) or 0.98 (0.78-1.24), respectively. Among the other parameters that 
are usually employed to assess for DIC, mean (min-max) fibrinogen was greatly 
increased 680 mg/dL (234-1,344); platelet count was normal(increased) 348x109/L (59-
577); D dimer was greatly increased 4,877 ng/mL (1,197-16,954). Results for the other 
parameters of hemostasis were available for 11 patients and were as follows: factor VIII 
[297 U/dL (223-470)] and von Willebrand factor antigen [529 (210-863)] were greatly 
increased. Antithrombin [74 U/dL (45-120)] was slightly decreased. Protein C [122 U/dL 
(75-177)] was increased and the free protein S antigen [69 U/dL (33-109)] was marginally 
decreased.
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Overall, the results of this study support the concept that the hypercoagulability displayed 
by TEG is due to the profound derangement of hemostasis and is the likely contributor to 
pulmonary embolism and/or deep vein thrombosis of the lower limbs observed in patients 
with Covid-19. Other contributions may stem from the endothelial dysfunction (as shown 
by the greatly increased levels of von Willebrand factor, both antigen and ristocetin co-
factor) and sepsis subsequent to the massive infection. There are few studies dealing 
with hemostasis derangement and Covid-19. Tang et al [5] reported results compatible 
with a state of DIC, which were however based on such biochemical markers as high 
fibrin degradation products (e.g., D dimer), prolonged PT/APTT and low platelet counts. 
Part of the above results are confirmed in this report (e.g., increased D dimer), but other 
signs of DIC such as prolonged PT/APTT are not confirmed. Furthermore, reduced 
platelet counts and low fibrinogen clotting activity, which are pathognomonic signs of DIC 
are normal or even increased in our cohort and do not support the consumption 
coagulopathy, which is the hallmark of acute DIC. The reasons for the discrepancy is 
unclear. It cannot be excluded that the two populations, although both admitted to the 
ICU, were at different time points during the course of the disease progression. 
Cumulatively, our results suggest that patients with Covid-19 may develop a state of 
hypercoagulability as shown by the TEG parameters, increased factor VIII, von 
Willebrand factor and fibrinogen. This hypercoagulability could contribute (in addition to 
other causes) to the development of pulmonary embolism and/or deep vein thrombosis of 
the lower limbs. The reasons for the observed hypercoagulability are unknown. Plasma 
hypercoagulability may be commonly due to increased levels of pro-coagulant factors, 
decreased levels of the naturally occurring anti-coagulant factors or both. In this cohort 
factor VIII, which is one of the most potent triggers of hypercoagulability, was strongly 
increased (up to 460 U/dL, Table1) and the main naturally occurring anticoagulants are 
(near)normal (i.e., antithrombin) or even increased (i.e., protein C). Additional 
explanations for the hypercoagulability may be the presence of high numbers of 
circulating microvesicles. These moieties are cytoplasmic microparticles stemming from 
platelets or monocytes, which carry the procoagulant asset of the parent cells (i.e., tissue 
factor from monocytes and phosphatydil-serine from platelets). Microvesicles are known 
determinants of venous thromboembolism [6]. Indeed, increased numbers of circulating 
microvesicles have been reported in septic patients [7] and it is therefore possible that A
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they are also increased in patients with Covid-19. Neutrophil external traps (NET), which 
are released from activated neutrophils, constitute a mixture of nucleic DNA, histones 
and nucleosomes [8], which may add procoagulant substances associated with plasma 
hypercoagulability and increased risk of thrombosis in animal models and in humans [9, 
10]. It is well known that inflammation is closely associated with thrombosis. Pro-
inflammatory cytokines are established modulators of coagulation and fibrinolysis 
activation [11] and might constitute another formidable trigger to explain the procoagulant 
imbalance in patients with Covid-19. Finally, endothelial derangement may play an 
additional role. Elevated von Willebrand factor levels found in this study (up to 863 U/dL, 
Table 1) may be taken as surrogate markers of endothelial derangement in Covid-19. 
Whatever the reasons, the signs of hypercoagulability observed in this study would 
support the use of antithrombotic drugs in patients with Covid-19 to quench the pro-
coagulant imbalance and possibly venous thromboembolism (either deep vein 
thrombosis of the lower limbs or pulmonary embolism).
Some limitations of this study should be recognized. First, blood collection and laboratory 
tests were not performed for all consecutive patients seen at the ICU in a pre-specified 
period (i.e., 13-24th March 2020). It is therefore possible that there may be a selection 
bias and that the sample size is not large enough to represent the whole population of 
Covid-19 patients admitted to ICU. Second, the direct signs of hypercoagulability 
observed in this cohort rest mainly on the TEG parameters. This device is used to guide 
transfusion in critically ill hemorrhagic patients [12] and more rarely to detect 
hypercoagulability, although there are observations showing that TEG is also useful to 
detect hypercoagulability [13-15]. These limitations notwithstanding, it is of interest to 
note that a state of hypercoagulability has been shown in these patients. Although, a 
recent study showed that the antithrombotic prophylaxis with LMWH or unfractionated 
heparin is associated with decreased mortality in severe Covid-19 patients [16], the 
benefit/risk ratio of using other anticoagulants, as well as the timing of starting 
anticoagulation at which dose and how long for, should be evaluated by appropriate 
randomized clinical trials. 
In conclusion, the results observed in our cohort of patient with Covid-19 are not 
consistent with DIC, rather they support hypercoagulability together with a severe 
inflammatory state. The hypercoagulability in addition to the clinical finding of pulmonary A
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embolism and/or deep vein thromboses of the lower limbs observed in some of the 
Covid-19 patients support antithrombotic prophylaxis with low molecular weight or 
unfractionated heparin. Escalating the dose from prophylaxis to treatment needs careful 
consideration based on the benefit/ratio risk at least until clinical trials will inform 
clinicians on decision making. 
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Table 1. TEG (in the presence of heparinase), hemostasis and other biochemical 
parameters for the investigated population. PT ratio, prothrombin time ratio 
(patient/normal). APTT ratio, activated partial thromboplastin ratio (patient/normal). VWF 
Ag, von Willebrand factor antigen. VWF RiCof, von Willebrand factor ristocetin cofactor.
Observations
No (%) <Lower limit or 
>Upper limit
No (%) <  or  > Mean 
NormalReference Range
Mean (Lower-
Upper limits) No* Mean (min-max)
<Lower 
limit
>Upper 
limit <Mean >Mean
Age 24 56 (23 - 71)     
PT ratio 1.02 (0.84-1.20) 30 1.16 (0.99 - 1.50) 0 (0) 8 (27) 1 (3) 29 (97)
APTT ratio 1.00 (0.86-1.20) 30 0.98 (0.78 - 1.24) 5 (17) 2 (7) 19 (63) 11 (37)
D Dimer (ng/mL, 
FEU) <500 30 4877 (1197 - 16954) 0 (0) 30 (100)
Fibrinogen 
(mg/dL) 258 (165.0-350) 30 680 (234 - 1344) 0 (0) 28 (93) 1 (3) 29 (97)
Antithrombin 
(U/dL) 102 (82-122) 11 74 (45 - 120) 6 (55) 0 (0) 10 (91) 1 (9)
Protein C (U/dL) 113 (6-165) 11 122 (75 - 177) 0 (0) 2 (18) 4 (36) 7 (64)
Protein S free 
antigen (U/dL)  11 69 (33 - 109)     
Factor VIII 
(U/dL) 99 (51-147) 11 297 (223 - 470) 0 (0) 11 (100) 0 (0) 11 (100)
VWF antigen 
(U/dl) 103 (40-165) 11 529 (210 - 863) 0 (0) 11 (100) 0 (0) 11 (100)
VWF RiCof 
(U/dL) 96 (41-151) 11 387 (195 - 550) 0 (0) 11 (100) 0 (0) 11 (100)
TEG – R (min) 10.5 (4.0-8.0) 30 6.3 (3.0 - 11.9) 4 (13) 6 (20) 28 (93) 2 (7)
TEG – K (min) 2.1 (0.0-4.0) 30 1.5 (0.8 - 2.9) 0 (0) 0 (0) 27 (90) 3 (10)
TEG - Angle K 
(degree) 61.7 (47.0-74.0) 30 69.4 (51.1 - 78.5) 0 (0) 12 (40) 7 (23) 23 (77)
TEG – MA (mm) 70.8 (54.0-72.0) 30 79.1 (58.0 - 92.0) 0 (0) 25 (83) 4 (13) 26 (87)
TEG - LY30 0 (0-8) 29 7.8 (0 - 54.3) 0 (0) 7 (23) 29 (100) 0 (0)
Platelets (x109/L) 265 (130-400) 30 348 (59 - 577) 1 (3) * 0 (0)§ 7 (23) 23 (77)
C-reactive <0.5 30 16.1 (3.9 - 34.2) 0 (0) 30 (100)   
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protein (mg/dL)
Ferritin (µg/L) 11 1485 (452 - 5792)
*platelets <50x109/L
§platelets >50<100x109/L
*Measurements were repeated on two consecutive days in 6 patients
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LEGENDS TO FIGURES
Fig 1. Result distribution of the maximal clot amplitude (MA) in the patient population. 
Solid and broken lines represent the univariate density estimation and the limits of the 
reference range, respectively.
Fig 2. Typical TEG tracings. Broken and solid lines represent a healthy subject and a 
COVID-19 patient, respectively. The Covid-19 patient was characterized by the following 
TEG parameters: R=5.5 min. K=0.9 min. Angle K=78.8°. MA=88.8 mm and by the 
following hemostasis parameters: Prothrombin time ratio=1.19. Activated partial 
thromboplastin time ratio=1.21. D dimer=1,829 ng/mL. Fibrinogen=849 mg/mL. 
Antithrombin=87 U/dL; Protein C=116 U/dL. Protein S (free antigen)=68 U/dL. Factor 
VIII=269 U/dL. von Willebrand factor (antigen)=476 U/dL. von Willebrand factor (ristocetin 
cofactor)=347 U/dL. Platelet count=546x109/L.
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